Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
Sara Lega, Becky L. Phan, Casey J. Rosenthal, et al.
Inflammatory Bowel Diseases (2018) Vol. 25, Iss. 1, pp. 134-141
Closed Access | Times Cited: 79

Showing 26-50 of 79 citing articles:

Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Rheumatology (2020) Vol. 32, Iss. 4, pp. 371-379
Open Access | Times Cited: 27
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
Antonello Di Paolo, Giacomo Luci
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 25
Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor
Niels Vande Casteele, María T. Abreu, Sarah N. Flier, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 2, pp. 465-467.e2
Open Access | Times Cited: 22
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
Sonia Facchin, Andrea Buda, Romilda Cardin, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 21
Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease
Raffaella Franca, Debora Curci, Marianna Lucafò, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 7, pp. 527-539
Open Access | Times Cited: 23
Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis
Faith D. Ihekweazu, Tatiana Fofanova, Ryan Palacios, et al.
Journal of Pediatric Surgery (2020) Vol. 55, Iss. 9, pp. 1815-1823
Open Access | Times Cited: 22
Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis
Joseph Runde, Amarachi Erondu, Shintaro Akiyama, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 9, pp. 1386-1394
Open Access | Times Cited: 12
Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.
Jessica Breton, Arthur Kastl, Máire A. Conrad, et al.
Gastroenterología y Hepatología (2020) Vol. 16, Iss. 8, pp. 400-414
Closed Access | Times Cited: 20
Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?
Carla J. Gargallo-Puyuelo, Viviana Laredo, Fernando Gomollón
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 17
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Determination of Serum Infliximab Concentration by Point‐of‐care Devices in Children With Inflammatory Bowel Disease
Debora Curci, Marianna Lucafò, Adriana Cifù, et al.
Journal of Pediatric Gastroenterology and Nutrition (2019) Vol. 69, Iss. 4, pp. 474-479
Open Access | Times Cited: 19
Bayes‐based dosing of infliximab in inflammatory bowel diseases: Short‐term efficacy
Eugènia Santacana Juncosa, Lorena Rodríguez‐Alonso, Ariadna Padullés, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 2, pp. 494-505
Open Access | Times Cited: 16
Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
Akshay Kapoor, Eileen Crowley
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 15
Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease
Marianna Lucafò, Debora Curci, Matteo Bramuzzo, et al.
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 14
Therapeutic Drug Monitoring of Biologics in Crohn’s Disease
Laurie B. Grossberg, Adam S. Cheifetz, Konstantinos Papamichael
Gastroenterology Clinics of North America (2022) Vol. 51, Iss. 2, pp. 299-317
Closed Access | Times Cited: 10
The New Proactive Approach and Precision Medicine in Crohn’s Disease
Eran Zittan, Ian M. Gralnek, Marc S. Berns
Biomedicines (2020) Vol. 8, Iss. 7, pp. 193-193
Open Access | Times Cited: 14
Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
Kaija-Leena Kolho
Frontiers in Pediatrics (2021) Vol. 8
Open Access | Times Cited: 13
Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits
Emilio J. Laserna‐Mendieta, Sara Salvador‐Martín, Ignacio Marín‐Jiménez, et al.
Journal of Pharmaceutical and Biomedical Analysis (2021) Vol. 198, pp. 114003-114003
Closed Access | Times Cited: 13
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations
Ryan C. Ungaro, Jean‐Frédéric Colombel, Marla C. Dubinsky, et al.
Inflammatory Bowel Diseases (2021) Vol. 28, Iss. 4, pp. 649-651
Open Access | Times Cited: 13
A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease
Mathilde Barrau, Manon Duprat, Pauline Veyrard, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 4, pp. 633-643
Closed Access | Times Cited: 8
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction—A Prospective Trial
Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1757-1757
Open Access | Times Cited: 4
Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease
Pilar Navajas Hernández, Samer Mouhtar El Hálabi, Ana Caridad González Parra, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Biological therapy in pediatric age
Francesca Penagini, Lucia Cococcioni, Elena Pozzi, et al.
Pharmacological Research (2020) Vol. 161, pp. 105120-105120
Closed Access | Times Cited: 12
Optimized Infliximab Induction Predicts Better Long‐Term Clinical and Biomarker Outcomes Compared to Standard Induction Dosing
Sally Lawrence, Farah Faytrouni, Rachel E. Harris, et al.
Journal of Pediatric Gastroenterology and Nutrition (2022) Vol. 75, Iss. 5, pp. 601-607
Closed Access | Times Cited: 7
Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Konstantinos Papamichael, Niels Vande Casteele, Bincy Abraham, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 11, pp. 2978-2980.e2
Closed Access | Times Cited: 7

Scroll to top